Viatris Inc. · NASDAQ:VTRS
Viatris — Merger or Acquisition (October 2023)
5 slides from Viatris's merger presentation, Oct 1, 2023
Slide 1: Divestitures Announcement
Divestitures Announcement October 1, 2023 This document contains proprietary informationThis of Viatris document Inc. Unauthorized contains proprietary use, duplication, informationdissemination of Viatris Inc. orUnauthorized disclosure to use, third duplication, parties is strictly dissemination pr
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements”. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, Viatris announces agreements
Slide 3: Non-GAAP Measures
Non-GAAP Measures This presentation includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("U.S. GAAP"). These non-GAAP financial measures, including, but not limited to, 2022 e
Slide 4: Viatris Announces Agreements on Remaining Planned Divestitures
Viatris Announces Agreements on Remaining Planned Divestitures ‣ Upon closing, would achieve original total target multiple above 12x on 2022 estimated adjusted EBITDA for all planned divestitures ‣ Total gross proceeds from all divestitures (including the 2022 divestiture of the Company’s biosimila
Slide 5: Summary of Divestiture Transactions (1)
Summary of Divestiture Transactions (1) ‣ OTC products predominantly in European markets ‣ Includes 2 manufacturing sites, 1 R&D site, and potentially conveying headcount of ~700 OTC ‣ Retained OTC switch candidates, such as Viagra® and Dymista®, and select OTC products in certain markets ‣ Would be